Attenuating the experimental autoimmune encephalomyelitis model improves preclinical evaluation of candidate multiple sclerosis therapeutics.

However, in the case of AP, there was a highly significant difference between the therapeutic regimen and no treatment control ( p < 0.0001), showing that drug effect could be demonstrated by attenuation of disease aggressiveness.

also in 132,142 other papers